Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from WuXi AppTec Co., Ltd. Class H ( (HK:2359) ).
WuXi AppTec Co., Ltd. has announced the proposed adoption of the 2025 H Share Award and Trust Scheme, aimed at attracting, motivating, and retaining skilled personnel by offering equity incentives aligned with company performance. The scheme, pending shareholder approval at the 2024 AGM, seeks to modernize remuneration practices and align management and shareholder interests, supporting the company’s long-term growth and operational goals.
More about WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. is a company incorporated in the People’s Republic of China, operating in the pharmaceutical and biotechnology industry. It focuses on providing comprehensive research and development services, including drug discovery, development, and manufacturing, to support the pharmaceutical, biotech, and medical device industries globally.
YTD Price Performance: 14.16%
Average Trading Volume: 5,403,051
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$194.8B
See more data about 2359 stock on TipRanks’ Stock Analysis page.